Skip to content
Botulinum toxin type a
Nuceiva (botulinum toxin type a) is an unknown pharmaceutical. Botulinum toxin type a was first approved as Nuceiva on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
integumentary system physiological phenomenaD055827
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
daxxifyBiologic Licensing Application2023-03-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
blepharospasmD001764G24.5
dystoniaHP_0001332D004421G24
fissure in anoHP_0012390D005401K60.2
genetic skin diseasesD012873
muscle rigidityHP_0002063D009127
strabismusHP_0000486D013285H50.2
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
887 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Overactive urinary bladderD053201EFO_1000781N32.8151118161663
StrokeD020521EFO_0000712I63.9491614747
Cerebral palsyD002547G80281541440
TorticollisD014103HP_0000473F45.858117837
Muscle spasticityD009128HP_0001257151181136
Migraine disordersD008881EFO_0003821G432597627
Urinary incontinenceD014549HP_0000020R3214105524
Urge urinary incontinenceD053202EFO_0006865N39.413254315
HyperhidrosisD006945HP_00009753224415
BlepharospasmD001764G24.51354213
Show 78 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tennis elbowD013716EFO_1001896M77.1538
Plantar fasciitisD036981EFO_1001909M72.214227
SialorrheaD012798HP_0002307K11.75316
Temporomandibular joint disordersD013705M26.612215
VulvodyniaD056650N94.81134
HeadacheD006261HP_0002315R51224
ObesityD009765EFO_0001073E66.91213
Erectile dysfunctionD007172EFO_0004234F52.21323
Cluster headacheD003027HP_0012199G44.002213
ParesisD010291HP_0001269213
Show 26 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0133
Diabetes mellitusD003920EFO_0000400E08-E13123
Lower urinary tract symptomsD059411EFO_00080081113
Neck painD019547HP_0030833M54.22113
SmilingD012904112
Abdominal herniaD046449K46112
Major depressive disorderD003865EFO_0003761F22112
TendinopathyD052256EFO_1001434M77.922
Traumatic brain injuriesD000070642S0622
Back painD001416HP_0003418M54112
Show 48 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L4022
Hemorrhagic strokeD00008330211
Internal carotid artery dissectionD02021511
Vertebral artery dissectionD020217I77.7411
Myelodysplastic syndromesD009190D4611
Myeloid leukemia acuteD015470C92.011
Gingival overgrowthD019214K06.111
Treatment-resistant depressive disorderD06121811
Complex regional pain syndromesD020918EFO_100199811
Secondary headache disordersD05127111
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DystoniaD004421HP_0001332G2422
Diffuse esophageal spasmD015155EFO_1001785K22.422
StrabismusD013285HP_0000486H50.222
Alopecia areataD000506EFO_0004192L6322
ConstipationD003248HP_0002019K59.022
Hidradenitis suppurativaD017497L73.222
Activities of daily livingD00020311
BotulismD001906EFO_0005542A05.111
Pancreatic fistulaD01018511
Treatment outcomeD01689611
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBOTULINUM TOXIN TYPE A
INN
Description
Botulinum toxin, or botulinum neurotoxin (BoNT), is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It is also known as Botulin, the density of which is predicted to be 1.5±0.1 g/cm3. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
Classification
Neurotoxin
Drug classfluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL4297862
ChEBI ID
PubChem CID
DrugBankDB00083
UNII ID
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,652 documents
View more details
Safety
Black-box Warning
Black-box warning for: Daxxify
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,252 adverse events reported
View more details